RecruitingPhase 2Phase 3NCT03922542

Comparison of Standard vs. Accelerated Corneal Crosslinking

Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Progressive Keratoconus or Ectasia

Sponsor

Price Vision Group

Enrollment

510 participants

Start Date

Apr 16, 2019

Study Type

INTERVENTIONAL

Conditions

Keratoconus Ectasia Corneal

Summary

The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.

Eligibility

Min Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Riboflavin 0.1% and riboflavin 0.1% for people with ectasia corneal and keratoconus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 10 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTriboflavin 0.1%

Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes

COMBINATION_PRODUCTRiboflavin 0.1%

Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes

Locations(1)

Price Vision Group

Indianapolis, Indiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03922542

Related Trials

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

NCT076295571 location

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

NCT074009521 location